World Prostate Cancer Therapeutics Market Analysed by iGATE Research in In-demand Study Available at

07 Jul 2015 • by Natalie Aster

LONDON – The world prostate cancer therapeutics market is gathering speed, driven by the global ageing population, drug product innovations, developments in genomics and proteomics, as well as by the rise of the hormonal therapy markets. However, the high price of prostate cancer drugs, low success rates of clinical studies and possible side effects of treatments, amid others, could hinder growth in the sector.

Chemotherapy was the second-place therapy for prostate cancer as of 2014, which is expected to be outpaced by the targeted therapy in the offing; whilst the last position in the prostate cancer therapeutics market is occupied by immunotherapy for prostate cancer.

Zytiga (abiraterone) took the lead in the prostate cancer drugs market in 2014. The medication is facing strong competition from Xtandi (enzalutamide) drugs, which are likely to displace Zytiga as the dominant prostate cancer drugs. In the prostate cancer drugs market, Leuplin and Zoladex came third and fourth, respectively, as of 2014. Their market shares are likely to plummet over the forecast period. Lupron ranks fifth. Bayer's targeted cancer drug Xofigo is also rapidly making good running due to benefits such as an upsurge in the overall survival and progression-free survival (PFS) with a profile of benign side-effects.

In-demand market research report “Global Prostate Cancer Therapeutics Market to 2020” developed by iGATE Research Pvt. Ltd. provides a comprehensive examination of the global prostate cancer therapeutics market. It casts light on prostate cancer incidence rates globally, offers an analysis of the prostate cancer therapy market and drug market shares, and provides an analysis of the prostate cancer therapy market by covering its 4 major segments and analysing each of them in terms of drugs sales during the historical and forecast period. The study also identifies and canvasses key driving factors and challenges in the worldwide prostate cancer therapy marketplace.  Additionally, extensive drug sales forecasts to 2020 are available in the study.

Historical data are provided for 2011-2014 and forecast figures are offered up to 2020.

Report Details:

Global Prostate Cancer Therapeutics Market to 2020
Published: May, 2015
Pages: 76
Price: US$ 1,000.00

More in-demand studies can be found at iGATE Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970